Celldex Therapeutics’ (CLDX) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Celldex Therapeutics (NASDAQ:CLDX) in a research report report published on Wednesday morning, Benzinga reports. The firm currently has a $80.00 price objective on the biopharmaceutical company’s stock.

A number of other brokerages have also weighed in on CLDX. TD Cowen began coverage on Celldex Therapeutics in a research note on Wednesday, December 20th. They issued an outperform rating on the stock. Cantor Fitzgerald reissued an overweight rating and set a $67.00 price objective on shares of Celldex Therapeutics in a report on Friday, March 22nd. Finally, Guggenheim upped their target price on Celldex Therapeutics from $72.00 to $90.00 and gave the stock a buy rating in a research note on Tuesday, February 27th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of Moderate Buy and an average target price of $66.00.

Celldex Therapeutics Stock Down 1.4 %

Shares of NASDAQ CLDX opened at $37.98 on Wednesday. The firm has a market capitalization of $2.12 billion, a P/E ratio of -13.05 and a beta of 1.49. The stock’s 50-day simple moving average is $42.03 and its two-hundred day simple moving average is $35.80. Celldex Therapeutics has a twelve month low of $22.11 and a twelve month high of $53.18.

Celldex Therapeutics (NASDAQ:CLDX) last announced its earnings results on Monday, February 26th. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.19. The business had revenue of $4.13 million for the quarter, compared to analyst estimates of $1.20 million. Celldex Therapeutics had a negative return on equity of 41.06% and a negative net margin of 2,054.46%. As a group, research analysts anticipate that Celldex Therapeutics will post -2.85 EPS for the current fiscal year.

Institutional Trading of Celldex Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Wellington Management Group LLP boosted its position in Celldex Therapeutics by 19.2% during the fourth quarter. Wellington Management Group LLP now owns 6,476,561 shares of the biopharmaceutical company’s stock valued at $256,860,000 after buying an additional 1,044,728 shares during the period. Eventide Asset Management LLC boosted its position in Celldex Therapeutics by 126.9% during the fourth quarter. Eventide Asset Management LLC now owns 3,630,013 shares of the biopharmaceutical company’s stock valued at $143,966,000 after buying an additional 2,030,013 shares during the period. BlackRock Inc. boosted its position in Celldex Therapeutics by 0.8% during the first quarter. BlackRock Inc. now owns 3,250,638 shares of the biopharmaceutical company’s stock valued at $116,958,000 after buying an additional 25,922 shares during the period. State Street Corp boosted its position in Celldex Therapeutics by 20.4% during the second quarter. State Street Corp now owns 3,228,852 shares of the biopharmaceutical company’s stock valued at $87,050,000 after buying an additional 546,124 shares during the period. Finally, Kynam Capital Management LP boosted its position in Celldex Therapeutics by 23.1% during the third quarter. Kynam Capital Management LP now owns 3,200,000 shares of the biopharmaceutical company’s stock valued at $88,064,000 after buying an additional 600,000 shares during the period.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.